Mutant and mislocalized cell surface nucleophosmin 1 as a diagnostic and therapeutic target of human disease
AssigneesChildren's Medical Center Corporation, Cambridge Enterprise Limited
InventorsRyan A. Flynn, Benson m. George, Konstantinos Tzelepis
Life of this patent
Estimating the term…
Abstract
Provided herein are antibodies specific for nucleophosmin 1 (NPM1), which are capable of binding to wild-type and/or mutant nucleophosmin 1 located on the surface of cells. These antibodies, as well as antibody conjugates comprising these antibodies, are useful for the detection and treatment of cancers in which NPM1 is expressed on the surface of cancer cells.
Claims82
An antibody that binds to nucleophosmin 1 (NPM1).
A method for treating a disease associated with a cell expressing cell surface nucleophosmin 1 (NPM1), the method comprising administering to a subject in need thereof an effective amount of an antibody or a conjugate that binds to NPM1.
Dependencies are inferred from the claim text.